Current Treatment of Advanced Prostate Cancer: The Balance between Efficacy and Safety

The publication of this content was funded by Sandoz. The views and opinions expressed are exclusively those of the speakers not necessarily of EMJ or Sandoz.

Part 1: Introductory Presentation, LEAN data, and Discussion

Part 2: Guidelines and Discussion

Part 3: Cardiovascular Perspectives and Discussion

Whilst the use of innovative treatment compounds have improved prostate cancer survival rates, long-term androgen deprivation therapy remains the backbone of many prostate cancer treatment regimens. 

Growing evidence supports early treatment intensification for prostate cancer. However, this approach requires greater effort to control cardiovascular (CV) side effects, and there are concerns over the relative safety of gonadotropin-releasing hormone agonists and antagonists. Concerns regarding the cardiotoxicity of androgen deprivation therapy have been explored in both clinical trials and real-world studies. 

In these videos, experts in urology and cardiology: 

• Present insights into CV safety from the Phase III HERO and PRONOUNCE trials, as well as evidence from real‑world registry studies.
• Provide an overview of the LEAN real-world study and recent CV safety results.
• Explore the latest clinical guideline recommendations, including prostate cancer guidelines and recommendations for CV risk assessment in patients receiving cancer therapy.
• Discuss how to optimise CV care, including the importance of multidisciplinary collaboration.
• Discuss cardiologists’ role in prostate cancer care to manage CV risk factors and ensure patients can receive the most effective treatments.

1. Department of Urology, Johanniter Hospital, Bonn, Germany
2. Department of Cardiology, Univ. Clinic of Internal Medicine II, Medical University of Vienna, Austria
3. Urologie 24, St. Theresien-Krankenhaus, Nuremberg, Germany; Department of Urology and Pediatric Urology, Friedrich-Alexander University, Erlangen, Germany